NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free XBIO Stock Alerts $4.09 +0.31 (+8.20%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$3.99▼$4.1350-Day Range$3.61▼$4.7252-Week Range$2.55▼$5.97Volume667 shsAverage Volume5,801 shsMarket Capitalization$6.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Xenetic Biosciences alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Xenetic Biosciences Stock (NASDAQ:XBIO)Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Read More XBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIO Stock News HeadlinesApril 10, 2024 | investing.comXenetic Biosciences Inc (XBIO)March 24, 2024 | finance.yahoo.comXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 22, 2024 | baystreet.caXenetic Dips on Full-Year ResultsMarch 22, 2024 | msn.comXenetic Biosciences reports FY resultsJanuary 18, 2024 | msn.comXenetic to advance DNase programme with UVA partnershipJanuary 4, 2024 | morningstar.comXenetic Biosciences Inc XBIODecember 11, 2023 | benzinga.comXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.November 30, 2023 | finance.yahoo.comMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO CompensationNovember 10, 2023 | benzinga.comXenetic Biosciences: Q3 Earnings InsightsNovember 10, 2023 | washingtonpost.comMediciNova: Q3 Earnings SnapshotOctober 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceJuly 13, 2023 | msn.comXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?May 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 5, 2023 | morningstar.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarMay 4, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentMay 3, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationApril 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)April 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformMarch 16, 2023 | finanznachrichten.deJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 16, 2023 | finance.yahoo.comJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesFebruary 23, 2023 | seekingalpha.comXBIO Xenetic Biosciences, Inc.February 21, 2023 | reuters.comXBIO.PH - | Stock Price & Latest News | ReutersJanuary 17, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with ChemotherapyDecember 15, 2022 | finance.yahoo.comWhy We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At AllSee More Headlines Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIO CUSIPN/A CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees4Year Founded2011Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,140,000.00 Net Margins-162.84% Pretax Margin-162.79% Return on Equity-36.43% Return on Assets-33.74% Debt Debt-to-Equity RatioN/A Current Ratio11.84 Quick Ratio11.84 Sales & Book Value Annual Sales$2.54 million Price / Sales2.48 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.64Miscellaneous Outstanding Shares1,540,000Free Float1,402,000Market Cap$6.30 million OptionableNot Optionable Beta2.60 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Jeffrey F. Eisenberg (Age 53)CEO & Director Mr. James F. Parslow (Age 54)CFO, COO & Corp. Sec. Dr. Curtis A. Lockshin (Age 59)Chief Scientific Officer Key CompetitorsAvenue TherapeuticsNASDAQ:ATXIHoth TherapeuticsNASDAQ:HOTHAyala PharmaceuticalsNASDAQ:ADXSVaccinexNASDAQ:VCNXAinosNASDAQ:AIMDView All Competitors XBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Xenetic Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares. View XBIO analyst ratings or view top-rated stocks. How have XBIO shares performed in 2024? Xenetic Biosciences' stock was trading at $3.45 at the beginning of the year. Since then, XBIO stock has increased by 18.5% and is now trading at $4.0899. View the best growth stocks for 2024 here. Are investors shorting Xenetic Biosciences? Xenetic Biosciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 2,800 shares, an increase of 64.7% from the March 31st total of 1,700 shares. Based on an average trading volume of 5,800 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.2% of the company's stock are short sold. View Xenetic Biosciences' Short Interest. When is Xenetic Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our XBIO earnings forecast. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences Inc (NASDAQ:XBIO) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.10. The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.68 million. Xenetic Biosciences had a negative net margin of 162.84% and a negative trailing twelve-month return on equity of 36.43%. When did Xenetic Biosciences' stock split? Xenetic Biosciences shares reverse split before market open on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX). How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
